Home › Companies › Keros Therapeutics, Inc. › 2025-2026
Download data (CSV): ballot items · votes by manager · column guide.
Compiled from SEC Form N-PX filings and Keros Therapeutics, Inc.’s Form 8-K, filed June 3, 2026 (Item 5.07 on EDGAR). Page generated November 20, 2026.
Meeting of June 3, 2026: 4 items on Keros Therapeutics, Inc.’s Form 8-K, filed June 3, 2026: 2 elected · 2 approved.
Significant dissent: 1 director (33.8% against).
Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided
Proxy season: 2023-2024 2024-2025 2025-2026
Activist investors: Nantahala Capital (13F, 7.6%, as of September 30, 2026)
Explore Keros Therapeutics, Inc. in the interactive database Compare manager voting policies
These tallies are Keros Therapeutics, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 3, 2026 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Jean-Jacques Bienaimé | 10,093,559 | -- | -- | 5,156,153 | 2,243,514 | 66% | Elected | — |
| Elect Director: Charles Newton | 14,716,598 | -- | -- | 533,114 | 2,243,514 | 97% | Elected | — |
| 2. Ratification of the Selection by the Audit Committee of the Board of Directors of Deloitte & Touche LLP as the Independent Registered Public Accounting Firm of the Company for its Fiscal Year Ending December 31, 2026 | 16,708,279 | 783,953 | 994 | -- | -- | 96% | Approved | — |
| 3. Advisory Vote on Executive Compensation | 14,273,625 | 974,049 | 2,038 | -- | 2,243,514 | 94% | Approved | — |
Source: Keros Therapeutics, Inc., Form 8-K, filed with the SEC on June 3, 2026 — read the filing on EDGAR.
See voting trends for Health Care companies, 2025-2026: shareholder support by sector and by company size.
180 asset managers disclosed a vote on at least one Keros Therapeutics, Inc. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 4 wordings of this item as funds reported it.
97% Majority: yes · of votes cast
Description as filed by funds: To elect the two (2) nominees for Class III director named below to hold office until the 2029 Annual Meeting of Stockholders: Charles Newton
Keros Therapeutics, Inc.’s own tally for this item (“Elect Director: Charles Newton”): 14,716,598 for, 533,114 withheld, per its Form 8-K filed June 3, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Proposal 1 – Election of Directors The Company's stockholders elected the two persons listed below as directors, each to serve until the Company's 2029 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified.”
Support: 97% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 60 asset managers below reported 5,780,807 for, 14,730 withheld, 1 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 1,475,943 | 0 | 1 | 0 | For |
| BlackRock | 1,116,062 | 0 | 0 | 0 | For |
| Fidelity | 614,783 | 0 | 0 | 0 | For |
| Federated Hermes | 514,400 | 0 | 0 | 0 | For |
| TIAA | 260,385 | 0 | 0 | 0 | For |
| Charles Schwab | 179,991 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 162,294 | 0 | 0 | 0 | For |
| EA Series Trust | 145,517 | 0 | 0 | 0 | For |
| OLD WESTBURY FUNDS INC | 143,853 | 0 | 0 | 0 | For |
| Dimensional | 123,808 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 98,754 | 0 | 0 | 0 | For |
| Nationwide | 90,975 | 0 | 0 | 0 | For |
| SEI | 73,492 | 0 | 0 | 0 | For |
| American Century | 66,359 | 0 | 0 | 0 | For |
| Equitable | 62,765 | 0 | 0 | 0 | For |
| Invesco | 61,793 | 0 | 0 | 0 | For |
| Principal Exchange-Traded Funds | 58,899 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 49,500 | 0 | 0 | 0 | For |
| GuideStone | 49,297 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 47,584 | 0 | 0 | 0 | For |
| Goldman Sachs | 42,218 | 0 | 0 | 0 | For |
| MFS | 40,860 | 0 | 0 | 0 | For |
| SEI Exchange Traded Funds | 35,747 | 0 | 0 | 0 | For |
| AQR | 34,582 | 0 | 0 | 0 | For |
| WisdomTree | 31,176 | 0 | 0 | 0 | For |
Showing the 25 largest of 60 asset managers. All 60 are in the interactive database (link above).
Combines 7 wordings of this item as funds reported it.
66% Majority: yes · of votes cast
Description as filed by funds: To elect the two (2) nominees for Class III director named below to hold office until the 2029 Annual Meeting of Stockholders: Jean-Jacques Bienaime
Keros Therapeutics, Inc.’s own tally for this item (“Elect Director: Jean-Jacques Bienaimé”): 10,093,559 for, 5,156,153 withheld, per its Form 8-K filed June 3, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Proposal 1 – Election of Directors The Company's stockholders elected the two persons listed below as directors, each to serve until the Company's 2029 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified.”
Support: 66% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 60 asset managers below reported 4,630,028 for, 1,165,499 withheld, 11 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 1,475,234 | 0 | 11 | 699 | For |
| BlackRock | 1,116,062 | 0 | 0 | 0 | For |
| Fidelity | 614,783 | 0 | 0 | 0 | For |
| Federated Hermes | 514,400 | 0 | 0 | 0 | For |
| TIAA | 260,385 | 0 | 0 | 0 | For |
| Charles Schwab | 179,991 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 162,294 | 0 | 0 | 0 | For |
| EA Series Trust | 0 | 0 | 0 | 145,517 | Withhold |
| OLD WESTBURY FUNDS INC | 0 | 0 | 0 | 143,853 | Withhold |
| Dimensional | 0 | 0 | 0 | 123,808 | Withhold |
| Columbia Threadneedle | 98,754 | 0 | 0 | 0 | For |
| Nationwide | 9,748 | 0 | 0 | 81,227 | Mixed |
| SEI | 0 | 0 | 0 | 73,492 | Withhold |
| American Century | 0 | 0 | 0 | 66,359 | Withhold |
| Equitable | 43,165 | 0 | 0 | 19,600 | Mixed |
| Invesco | 61,793 | 0 | 0 | 0 | For |
| Principal Exchange-Traded Funds | 0 | 0 | 0 | 58,899 | Withhold |
| BRIDGEWAY FUNDS INC | 0 | 0 | 0 | 49,500 | Withhold |
| GuideStone | 0 | 0 | 0 | 49,297 | Withhold |
| QUANTITATIVE MASTER SERIES LLC | 47,584 | 0 | 0 | 0 | For |
| Goldman Sachs | 0 | 0 | 0 | 42,218 | Withhold |
| MFS | 0 | 0 | 0 | 40,860 | Withhold |
| SEI Exchange Traded Funds | 0 | 0 | 0 | 35,747 | Withhold |
| AQR | 0 | 0 | 0 | 34,582 | Withhold |
| WisdomTree | 0 | 0 | 0 | 31,176 | Withhold |
Showing the 25 largest of 60 asset managers. All 60 are in the interactive database (link above).
Combines 2 wordings of this item as funds reported it.
94% Approved · of votes cast
Prior year: 81.7% for (June 4, 2025 meeting) ▲ 11.9 pts
Description as filed by funds: TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS AS DISCLOSED IN THE ACCOMPANYING PROXY STATEMENT.
Keros Therapeutics, Inc.’s own tally for this item (“3. Advisory Vote on Executive Compensation”): 14,273,625 for, 974,049 against — passed, per its Form 8-K filed June 3, 2026 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Proposal 3 – Advisory Vote on Executive Compensation The Company's stockholders approved, on a non-binding advisory basis, Proposal 3.”
Support: 94% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 1,475,943 | 1 | 0 | 0 | For |
| BlackRock | 1,116,062 | 0 | 0 | 0 | For |
| Fidelity | 614,783 | 0 | 0 | 0 | For |
| Federated Hermes | 514,400 | 0 | 0 | 0 | For |
| TIAA | 260,385 | 0 | 0 | 0 | For |
| Charles Schwab | 179,991 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 162,294 | 0 | 0 | 0 | For |
| EA Series Trust | 145,517 | 0 | 0 | 0 | For |
| OLD WESTBURY FUNDS INC | 143,853 | 0 | 0 | 0 | For |
| Dimensional | 123,808 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 98,754 | 0 | 0 | 0 | For |
| Nationwide | 90,975 | 0 | 0 | 0 | For |
| SEI | 73,492 | 0 | 0 | 0 | For |
| American Century | 0 | 66,359 | 0 | 0 | Against |
| Equitable | 62,765 | 0 | 0 | 0 | For |
| Invesco | 61,793 | 0 | 0 | 0 | For |
| Principal Exchange-Traded Funds | 58,899 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 49,500 | 0 | 0 | 0 | For |
| GuideStone | 49,297 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 47,584 | 0 | 0 | 0 | For |
| Goldman Sachs | 42,218 | 0 | 0 | 0 | For |
| MFS | 40,860 | 0 | 0 | 0 | For |
| SEI Exchange Traded Funds | 35,747 | 0 | 0 | 0 | For |
| AQR | 34,582 | 0 | 0 | 0 | For |
| WisdomTree | 31,176 | 0 | 0 | 0 | For |
Fund voting reports, all 59 managers: 5,712,362 for, 83,120 against. Showing the 25 largest; every one is in the interactive database (link above).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Nantahala Capital Management, LLC | 1,326,947 | 0 | 0 | 0 | For |
| BlackRock | 923,549 | 0 | 0 | 0 | For |
| ORBIMED ADVISORS LLC | 759,155 | 0 | 0 | 0 | For |
| Federated Hermes | 680,516 | 0 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 672,760 | 0 | 0 | 0 | For |
| State Street | 524,774 | 0 | 0 | 0 | For |
| Madison Avenue Partners, LP | 0 | 452,277 | 0 | 0 | Against |
| DE Shaw | 439,050 | 0 | 0 | 0 | For |
| JACOBS LEVY EQUITY MANAGEMENT, INC | 403,443 | 0 | 0 | 0 | For |
| Two Sigma | 326,214 | 0 | 0 | 0 | For |
| BESSEMER INVESTMENT MANAGEMENT LLC | 287,706 | 0 | 0 | 0 | For |
| Nuveen | 262,332 | 0 | 0 | 0 | For |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | 244,638 | 0 | 0 | 0 | For |
| AQR | 237,506 | 0 | 0 | 0 | For |
| Charles Schwab | 180,024 | 0 | 0 | 0 | For |
| Citadel | 167,546 | 0 | 0 | 0 | For |
| MACKENZIE FINANCIAL CORP | 152,450 | 0 | 0 | 0 | For |
| Vanguard | 144,141 | 0 | 0 | 0 | For |
| WELLS FARGO CLEARING SERVICES, LLC | 140,000 | 0 | 0 | 0 | For |
| ACADIAN ASSET MANAGEMENT LLC | 123,252 | 0 | 0 | 0 | For |
| Northern Trust | 119,313 | 0 | 0 | 0 | For |
| SEI | 109,666 | 0 | 0 | 0 | For |
| MELLON INVESTMENTS Corp | 104,690 | 0 | 0 | 0 | For |
| Point72 | 90,382 | 0 | 0 | 0 | For |
| Invesco | 86,714 | 0 | 0 | 0 | For |
Institutional-manager reports, all 138 managers: 9,811,083 for, 580,936 against. Showing the 25 largest; every one is in the interactive database (link above).
96% Approved · of votes cast
Prior year: 99.2% for (June 4, 2025 meeting) ▼ 3.7 pts
Description as filed by funds: TO RATIFY THE SELECTION BY THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS OF DELOITTE & TOUCHE LLP AS THE INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM OF THE COMPANY FOR ITS FISCAL YEAR ENDING DECEMBER 31, 2026.
Keros Therapeutics, Inc.’s own tally for this item (“2. Ratification of the Selection by the Audit Committee of the Board of Directors of Deloitte & Touche LLP as the Independent Registered Public Accounting Firm of the Company for its Fiscal Year Ending December 31, 2026”): 16,708,279 for, 783,953 against — passed, per its Form 8-K filed June 3, 2026 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Proposal 2 – Ratification of the Selection by the Audit Committee of the Board of Directors of Deloitte & Touche LLP as the Independent Registered Public Accounting Firm of the Company for its Fiscal Year Ending December 31, 2026 The Company's stockholders approved Proposal 2.”
Support: 96% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 60 asset managers below reported 5,795,537 for, 1 against.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 1,475,943 | 1 | 0 | 0 | For |
| BlackRock | 1,116,062 | 0 | 0 | 0 | For |
| Fidelity | 614,783 | 0 | 0 | 0 | For |
| Federated Hermes | 514,400 | 0 | 0 | 0 | For |
| TIAA | 260,385 | 0 | 0 | 0 | For |
| Charles Schwab | 179,991 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 162,294 | 0 | 0 | 0 | For |
| EA Series Trust | 145,517 | 0 | 0 | 0 | For |
| OLD WESTBURY FUNDS INC | 143,853 | 0 | 0 | 0 | For |
| Dimensional | 123,808 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 98,754 | 0 | 0 | 0 | For |
| Nationwide | 90,975 | 0 | 0 | 0 | For |
| SEI | 73,492 | 0 | 0 | 0 | For |
| American Century | 66,359 | 0 | 0 | 0 | For |
| Equitable | 62,765 | 0 | 0 | 0 | For |
| Invesco | 61,793 | 0 | 0 | 0 | For |
| Principal Exchange-Traded Funds | 58,899 | 0 | 0 | 0 | For |
| BRIDGEWAY FUNDS INC | 49,500 | 0 | 0 | 0 | For |
| GuideStone | 49,297 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 47,584 | 0 | 0 | 0 | For |
| Goldman Sachs | 42,218 | 0 | 0 | 0 | For |
| MFS | 40,860 | 0 | 0 | 0 | For |
| SEI Exchange Traded Funds | 35,747 | 0 | 0 | 0 | For |
| AQR | 34,582 | 0 | 0 | 0 | For |
| WisdomTree | 31,176 | 0 | 0 | 0 | For |
Showing the 25 largest of 60 asset managers. All 60 are in the interactive database (link above).
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 19,791,837 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Vanguard | 7.46% |
| 2 | BlackRock | 5.64% |
| 3 | Fidelity | 3.11% |
| 4 | Federated Hermes | 2.60% |
| 5 | TIAA | 1.32% |
| 6 | Charles Schwab | 0.91% |
| 7 | Bridge Builder Trust | 0.82% |
| 8 | EA Series Trust | 0.74% |
| 9 | OLD WESTBURY FUNDS INC | 0.73% |
| 10 | Dimensional | 0.63% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Nantahala Capital Management, LLC | 6.70% |
| 2 | BlackRock | 4.67% |
| 3 | ORBIMED ADVISORS LLC | 3.84% |
| 4 | Federated Hermes | 3.44% |
| 5 | GEODE CAPITAL MANAGEMENT, LLC | 3.40% |
| 6 | State Street | 2.65% |
| 7 | Madison Avenue Partners, LP | 2.29% |
| 8 | DE Shaw | 2.22% |
| 9 | JACOBS LEVY EQUITY MANAGEMENT, INC | 2.04% |
| 10 | Two Sigma | 1.65% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.
| Holder | Shares | % outstanding | Source, as of |
|---|---|---|---|
| BlackRock | 2,411,793 | 12.19% | Form 13F, quarter ended March 31, 2026 |
| Jasbir Seehra, Ph.D. | 1,871,682 | 9.46% | Proxy statement (DEF 14A), table as of March 31, 2026 |
| Vanguard Group | 1,525,355 | 7.71% | Form 13F, quarter ended March 31, 2026 |
| Nantahala Capital Management, LLC | 1,360,419 | 6.87% | Schedule 13G, filed May 15, 2026 |
| Madison Avenue International LP | 823,707 | 4.16% | Schedule 13G, filed February 17, 2026 |
| Geode Capital | 681,460 | 3.44% | Form 13F, quarter ended March 31, 2026 |
| State Street | 561,730 | 2.84% | Form 13F, quarter ended March 31, 2026 |
| Citadel Advisors | 553,766 | 2.80% | Form 13F, quarter ended March 31, 2026 |
| D.E. Shaw | 509,608 | 2.57% | Form 13F, quarter ended March 31, 2026 |
| Renaissance Technologies | 453,482 | 2.29% | Form 13F, quarter ended March 31, 2026 |
Percentages above are of 19,791,837 shares outstanding, as reported by Keros Therapeutics, Inc. on its Form 10-Q dated May 8, 2026 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
At Keros Therapeutics, Inc.'s shareholder meeting held June 3, 2026, in the 2025-2026 proxy season, 180 asset managers reported votes on at least one of its 4 ballot items in their SEC Form N-PX filings, covering 848 separate fund positions. On the most widely held item on that ballot — TO APPROVE, ON AN ADVISORY BASIS, THE COMPENSATION OF THE COMPANY'S NAMED EXECUTIVE OFFICERS AS… — Keros Therapeutics, Inc.'s filing reports the proposal as approved, with 94% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: Keros Therapeutics, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 3, 2026.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Keros Therapeutics, Inc.’s 10-Q dated May 8, 2026. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.
Keros Therapeutics, Inc. proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).
Proxy Votes Now, “Keros Therapeutics (KROS) 2026 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/keros-therapeutics-inc/2026 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.